VIVA 2019: Perivascular temsirolimus could be “viable alternative” to prevent restenosis in BTK lesions

  • June 16, 2020
  • Medvest Capital
  • Mercator MedSystems
  • Comments Off on VIVA 2019: Perivascular temsirolimus could be “viable alternative” to prevent restenosis in BTK lesions
Scroll to top